Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2016

Open Access 01-12-2016 | Research article

Risk allelic load in Th2 and Th3 cytokines genes as biomarker of susceptibility to HPV-16 positive cervical cancer: a case control study

Authors: K. Torres-Poveda, A. I. Burguete-García, M. Bahena-Román, R. Méndez-Martínez, M. A. Zurita-Díaz, G. López-Estrada, K. Delgado-Romero, O. Peralta-Zaragoza, V. H. Bermúdez-Morales, D. Cantú, A. García-Carrancá, V. Madrid-Marina

Published in: BMC Cancer | Issue 1/2016

Login to get access

Abstract

Background

Alterations in the host cellular immune response allow persistent infections with High-Risk Human Papillomavirus (HR-HPV) and development of premalignant cervical lesions and cervical cancer (CC). Variations of immunosuppressive cytokine levels in cervix are associated with the natural history of CC. To assess the potential role of genetic host immunity and cytokines serum levels in the risk of developing CC, we conducted a case–control study paired by age.

Methods

Peripheral blood samples from patients with CC (n = 200) and hospital controls (n = 200), were used to evaluate nine biallelic SNPs of six cytokine genes of the adaptive immune system by allelic discrimination and cytokines serum levels by ELISA.

Results

After analyzing the SNP association by multivariate logistic regression adjusted by age, CC history and smoking history, three Th2 cytokines (IL-4, IL-6 and IL-10) and one Th3 (TGFB1) cytokine were significantly associated with CC. Individuals with at least one copy of the following risk alleles: T of SNP (−590C > T IL-4), C of SNP (−573G > C IL-6), A of SNP (−592C > A IL-10), T of SNP (−819C > T IL-10) and T of SNP (−509C > T TGFB1), had an adjusted odds ratio (OR) of 2.08 (95 % CI 1.475–2.934, p = 0.0001), an OR of 1.70 (95 % CI 1.208–2.404, p = 0.002), an OR of 1.87 (95 % CI 1.332–2.630, p = 0.0001), an OR of 1.67 (95 % CI 1.192–2.353, p = 0.003) and an OR of 1.91 (95 % CI 1.354–2.701, p = 0.0001), respectively, for CC. The burden of carrying two or more of these risk alleles was found to have an additive effect on the risk of CC (p trend = 0.0001). Finally, the serum levels of Th2 and Th3 cytokines were higher in CC cases than the controls; whereas IFNG levels, a Th1 cytokine, were higher in controls than CC cases.

Conclusion

The significant associations of five SNPs with CC indicate that these polymorphisms are potential candidates for predicting the risk of development of CC, representing a risk allelic load for CC and can be used as a biomarker of susceptibility to this disease.
Literature
1.
Arbyn M, Castellsagué X, de Sanjosé S, Bruni L, Saraiya M, Bray F, et al. Worldwide burden of cervical cancer in 2008. Ann Oncol. 2011;22(12):2675–86.CrossRefPubMed
2.
INEGI. Estadísticas de mortalidad. Cubos dinámicos y CONAPO 2012. Proyecciones de la población de México 2012–2050. 2012.
3.
Insinga RP, Perez G, Wheeler CM, Koutsky LA, Garland SM, Leodolter S, et al. Incident cervical HPV infections in young women: transition probabilities for CIN and infection clearance. Cancer Epidemiol Biomarkers Prev. 2011;20:287–96.CrossRefPubMed
4.
Conesa-Zamora P. Immune responses against virus and tumor in cervical carcinogenesis: treatment strategies for avoiding the HPV-induced immune escape. Gynecol Oncol. 2013;131(2):480–8.CrossRefPubMed
5.
Bermúdez-Morales VH, Gutierrez LX, Alcocer-Gonzalez JM, Burguete A, Madrid-Marina V. Correlation between IL-10 gene expression and HPV infection in cervical cancer: a mechanism for immune response escape. Cancer Invest. 2008;26(10):1037–43.CrossRefPubMed
6.
Torres-Poveda K, Burguete-García AI, Cruz M, Martínez-Nava GA, Bahena-Román M, Ortíz-Flores E, et al. The SNP at −592 of human IL-10 gene is associated with serum IL-10 levels and increased risk for human papillomavirus cervical lesion development. Infect Agent Cancer. 2012;7(1):32–40.CrossRefPubMedPubMedCentral
7.
Basavaraju U, Shebl FM, Palmer AJ, Berry S, Hold GL, El-Omar EM, et al. Cytokine gene polymorphisms, cytokine levels and the risk of colorectal neoplasia in a screened population of Northeast Scotland. Eur J Cancer Prev. 2015;24(4):296–304.CrossRefPubMed
8.
Zhang X, Zhang L, Tian C, Yang L, Wang Z. Genetic variants and risk of cervical cancer: epidemiological evidence, meta-analysis and research review. BJOG. 2014;121(6):664–74.CrossRefPubMed
9.
Muñoz N, Castellsagué X, de González AB, Gissmann L. Chapter 1: HPV in the etiology of human cancer. Vaccine. 2006;24 Suppl 3:S3/1–10.
10.
Louie KS, de Sanjose S, Diaz M, Castellsagué X, Herrero R, Meijer CJ, et al. Early age at first sexual intercourse and early pregnancy are risk factors for cervical cancer in developing countries. Br J Cancer. 2009;100(7):1191–7.CrossRefPubMedPubMedCentral
11.
Magnusson PK, Lichtenstein P, Gyllensten UB. Heritability of cervical tumours. Int J Cancer. 2000;88(5):698–701.CrossRefPubMed
12.
Alcocer-González JM, Berumen J, Taméz-Guerra R, Bermúdez-Morales V, Peralta-Zaragoza O, Hernández-Pando R, et al. In vivo expression of immunosuppressive cytokines in human papillomavirus-transformed cervical cancer cells. Viral Immunol. 2006;19(3):481–91.CrossRefPubMed
13.
Díaz-Benítez CE, Navarro-Fuentes KR, Flores-Sosa JA, Juárez-Díaz J, Uribe-Salas FJ, Román-Basaure E, et al. CD3zeta expression and T cell proliferation are inhibited by TGF-beta1 and IL-10 in cervical cancer patients. J Clin Immunol. 2009;29(4):532–44.CrossRefPubMed
14.
15.
Torres-Poveda K, Bahena-Román M, Madrid-González C, Burguete-García AI, Bermúdez-Morales VH, Peralta-Zaragoza O, et al. Role of IL-10 and TGF-β1 in local immunosuppression in HPV-associated cervical neoplasia. World J Clin Oncol. 2014;5(4):753–63.CrossRefPubMedPubMedCentral
16.
Shamran HA, Hamza SJ, Yaseen NY, Al-Juboory AA, Taub DD, Price RL, et al. Impact of single nucleotide polymorphism in IL-4, IL-4R genes and systemic concentration of IL-4 on the incidence of glioma in Iraqi patients. Int J Med Sci. 2014;11(11):1147–53.CrossRefPubMedPubMedCentral
17.
Tsai MH, Chen WC, Tsai CH, Hang LW, Tsai FJ. Interleukin-4 gene, but not the interleukin-1 beta gene polymorphism, is associated with oral cancer. J Clin Lab Anal. 2005;19(3):93–8.CrossRefPubMed
18.
Zheng Z, Li X, Li Z, Ma XC. IL-4 -590C/T polymorphism and susceptibility to liver disease: a meta-analysis and meta-regression. DNA Cell Biol. 2013;32(8):443–50.CrossRefPubMed
19.
Lim WY, Chen Y, Ali SM, Chuah KL, Eng P, Leong SS, et al. Polymorphisms in inflammatory pathway genes, host factors and lung cancer risk in Chinese female never-smokers. Carcinogenesis. 2011;32(4):522–9.CrossRefPubMed
20.
Castro FA, Haimila K, Sareneva I, Schmitt M, Lorenzo J, Kunkel N, et al. Association of HLA-DRB1, interleukin-6 and cyclin D1 polymorphisms with cervical cancer in the Swedish population—A candidate gene approach. Int J Cancer. 2009;125(8):1851–8.CrossRefPubMed
21.
Veerapaneni P, Kirma N, Nair HB, Hammes LS, Hall KL, Tekmal RR. Elevated aromatase expression correlates with cervical carcinoma progression. Gynecol Oncol. 2009;114:496–500.CrossRefPubMed
22.
Wei LH, Kuo ML, Chen CA, Cheng WF, Cheng SP, Hsieh FJ, et al. Interleukin-6 in cervical cancer: the relationship with vascular endothelial growth factor. Gynecol Oncol. 2001;82:49–56.CrossRefPubMed
23.
Shi TY, Zhu ML, He J, Wang MY, Li QX, Zhou XY, et al. Polymorphisms of the Interleukin 6 gene contribute to cervical cancer susceptibility in Eastern Chinese women. Hum Genet. 2013;132:301–12.CrossRefPubMed
24.
Grimm C, Watrowski R, Baumühlner K, Natter C, Tong D, Wolf A, et al. Genetic variations of interleukin-1 and −6 genes and risk of cervical intraepithelial neoplasia. Gynecol Oncol. 2011;121(3):537–41.CrossRefPubMed
25.
Bennermo M, Held C, Stemme S, Ericsson CG, Silveira A, Green F, et al. Genetic predisposition of the interleukin-6 response to inflammation: implications for a variety of major diseases? Clin Chem. 2004;50(11):2136–40.CrossRefPubMed
26.
Kong SY, Lee HL, Eom HS, Park WS, Yun T, Kim HJ, et al. Reference intervals for circulating angiogenic cytokines. Clin Chem Lab Med. 2008;46(4):545–50.CrossRefPubMed
27.
Kingo K, Rätsep R, Kõks S, Karelson M, Silm H, Vasar E, et al. Influence of genetic polymorphisms on interleukin-10 mRNA expression and psoriasis susceptibility. J Dermatol Sci. 2005;37:111–3.CrossRefPubMed
28.
Ni J, Ye Y, Teng F, Wu Q. Interleukin 10 polymorphisms and cervical cancer risk: a meta-analysis. Int J Gynecol Cancer. 2013;23(1):126–33.CrossRefPubMed
29.
Steinke JW, Barekzi E, Hagman J, Borish L. Functional Analysis of −571 IL-10 promoter polymorphism reveals a repressor element controlled by Sp1. J Immunol. 2004;173:3215–22.CrossRefPubMed
30.
Stanczuk GA, Sibanda EN, Perrey C, Chirara M, Pravica V, Hutchinson IV, et al. Cancer of the uterine cervix may be significantly associated with a gene polymorphism coding for increased IL-10 production. Int J Cancer. 2001;94(6):792–4.CrossRefPubMed
31.
Ding Q, Shi Y, Fan B, Fan Z, Ding L, Li F, et al. The Interleukin-10 Promoter Polymorphism rs1800872 (−592C.A), Contributes to Cancer Susceptibility: Meta-Analysis of 16 785 Cases and 19 713 Controls. PLoS ONE. 2013;8(2):e57246.CrossRefPubMedPubMedCentral
32.
Singh H, Jain M, Sachan R, Mittal B. Association of TNFA (−308G > A) and IL-10 (−819C > T) promoter polymorphisms with risk of cervical cancer. Int J Gynecol Cancer. 2009;19(7):1190–4.CrossRefPubMed
33.
Yu Z, Liu Q, Huang C, Wu M, Li G. The interleukin 10–819C/T polymorphism and cancer risk: a HuGE review and meta-analysis of 73 studies including 15,942 cases and 22,336 controls. OMICS. 2013;17(4):200–14.CrossRefPubMedPubMedCentral
34.
35.
Wang J, Ding Q, Shi Y, Cao Q, Qin C, Zhu J, et al. The interleukin-10-1082 promoter polymorphism and cancer risk: a meta-analysis. Mutagenesis. 2012;27(3):305–12.CrossRefPubMed
36.
Rees L, Wood N, Gillespie K, Lai K, Gaston K, Mathieson P. The interleukin-10-1082 G/A polymorphism: allele frequency in different populations and functional significance. Cell Mol Life Sci. 2002;59(3):560–9.CrossRefPubMed
37.
Matsumoto K, Oki A, Satoh T, Okada S, Minaguchi T, Onuki M, et al. Interleukin-10–1082 gene polymorphism and susceptibility to cervical cancer among Japanese women. Jpn J Clin Oncol. 2010;40:1113–6.CrossRefPubMed
38.
Poli F, Nocco A, Berra S, Scalamogna M, Taioli E, Longhi E, et al. Allele frequencies of polymorphisms of TNFA, IL-6, IL-10 and IFNG in an Italian Caucasian population. Eur J Immunogenet. 2002;29:237–40.CrossRefPubMed
39.
Barbisan G, Pérez LO, Contreras A, Golijow CD. TNF-α and IL-10 promoter polymorphisms, HPV infection, and cervical cancer risk. Tumor Biol. 2012;33:1549–56.CrossRef
40.
Shah R, Hurley CK, Posch PE. A molecular mechanism for the differential regulation of TGF-beta1 expression due to the common SNP -509C-T (c. -1347C > T). Hum Genet. 2006;120(4):461–9.CrossRefPubMed
41.
Singh H, Jain M, Mittal B. Role of TGF-beta1 (−509C > T) promoter polymorphism in susceptibility to cervical cancer. Oncol Res. 2009;18(1):41–5.CrossRefPubMed
42.
Ramos-Flores C, Romero-Gutiérrez T, Delgado-Enciso I, Maldonado GE, Plascencia VM, Vazquez-Vuelvas OF, et al. Polymorphisms in the genes related to angiogenesis are associated with uterine cervical cancer. Int J Gynecol Cancer. 2013;23(7):1198–204.CrossRefPubMed
43.
Liu L, Yang X, Chen X, Kan T, Shen Y, Chen Z, et al. Association between TNF-α polymorphisms and cervical cancer risk: a meta-analysis. Mol Biol Rep. 2012;39:2683–8.CrossRefPubMed
44.
Ding B, Fu S, Wang M, Yue C, Wang W, Zhou D, et al. Tumor necrosis factor α -308 G > A polymorphisms and cervical cancer risk: a meta-analysis. Int J Gynecol Cancer. 2012;22(2):213–9.CrossRefPubMed
45.
Pan F, Tian J, Ji CS, He YF, Han XH, Wang Y, et al. Association of TNF-α-308 and −238 Polymorphisms with Risk of Cervical Cancer: A Meta-analysis. Asian Pac J Cancer Prev. 2012;13(11):5777–83.CrossRefPubMed
46.
Jin Y. Association of Single Nucleotide Polymorphisms in Tumor Necrosis Factor-Alpha with Cervical Cancer Susceptibility. Cell Biochem Biophys. 2015;71(1):77–84.CrossRefPubMed
47.
Zhang H-L, Zhang YJ. A systemic assessment of the association between tumor necrosis factor alpha 308G/A polymorphism and risk of cervical cancer. Tumor Biol. 2013;34(3):1659–65.CrossRef
48.
Stanczuk GA, Sibanda EN, Tswana SA, Bergstrom S. Polymorphism at the −308- promoter position of the tumor necrosis factor-alpha (TNF-alpha) gene and cervical cancer. Int J Gynecol Cancer. 2003;13:14853.CrossRef
49.
Govan VA, Constant D, Hoffman M, Williamson AL. The allelic distribution of −308 Tumor Necrosis Factor-alpha gene polymorphism in South african women with cervical cancer and control women. BMC Cancer. 2006;6:24.CrossRefPubMedPubMedCentral
50.
Ivansson EL, Magnusson JJ, Magnusson PK, Erlich HA, Gyllensten UB. MHC loci affecting cervical cancer risk: distinguishing the effects of HLA-DQB1 and non-HLA genes TNF, LTA, TAP1 and TAP2. Genes Immun. 2008;9(7):613–23.CrossRefPubMed
51.
Calhoun ES, McGovern RM, Janney CA, Cerhan JR, Iturria SJ, Smith DI, et al. Host genetic polymorphism analysis in cervical cancer. Clin Chem. 2002;48(8):1218–24.PubMed
52.
Baena A, Leung JY, Sullivan AD, Landires I, Vasquez-Luna N, Quiñones-Berrocal J, et al. TNF-alpha promoter single nucleotide polymorphisms are markers of human ancestry. Genes Immun. 2002;3:482–7.CrossRefPubMed
53.
Kim K, Cho SK, Sestak A, Namjou B, Kang C, Bae SC. Interferon-gamma gene polymorphisms associated with susceptibility to systemic lupus erythematosus. Ann Rheum Dis. 2010;69(6):1247–50.CrossRefPubMed
54.
Li CJ, Dai Y, Fu YJ, Tian JM, Li JL, Lu HJ, et al. Correlations of IFN-γ genetic polymorphisms with susceptibility to breast cancer: a meta-analysis. Tumour Biol. 2014;35(7):6867–77.CrossRefPubMed
55.
Song SH, Lee JK, Lee NW, Saw HS, Kang JS, Lee KW. Interferon-gamma (IFN-gamma): a possible prognostic marker for clearance of high-risk human papillomavirus (HPV). Gynecol Oncol. 2008;108(3):543–8.CrossRefPubMed
56.
Lages EL, Belo AV, Andrade SP, Rocha MÂ, de Freitas GF, Lamaita RM, et al. Analysis of systemic inflammatory response in the carcinogenic process of uterine cervical neoplasia. Biomed Pharmacother. 2011;65(7):496–9.CrossRefPubMed
57.
Ali KS, Ali HY, Jubrael JM. Concentration levels of IL-10 and TNFα cytokines in patients with human papilloma virus (HPV) DNA+ and DNA− cervical lesions. J Immunotoxicol. 2012;9(2):168–72.CrossRefPubMed
58.
Chechlinska M, Kowalska M, Kaminska J. Cytokines as potential tumour markers. Expert Opin Med Diagn. 2008;2(6):691–711.CrossRefPubMed
59.
Arany I, Grattendick KG, Tyring SK. Interleukin-10 induces transcription of the early promoter of human papillomavirus type 16 (HPV16) through the 5′-segment of the upstream regulatory region (URR). Antiviral Res. 2002;55(2):331–9.CrossRefPubMed
Metadata
Title
Risk allelic load in Th2 and Th3 cytokines genes as biomarker of susceptibility to HPV-16 positive cervical cancer: a case control study
Authors
K. Torres-Poveda
A. I. Burguete-García
M. Bahena-Román
R. Méndez-Martínez
M. A. Zurita-Díaz
G. López-Estrada
K. Delgado-Romero
O. Peralta-Zaragoza
V. H. Bermúdez-Morales
D. Cantú
A. García-Carrancá
V. Madrid-Marina
Publication date
01-12-2016
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2016
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-016-2364-4

Other articles of this Issue 1/2016

BMC Cancer 1/2016 Go to the issue

Research article

KSHV gB associated RGD interactions promote attachment of cells by inhibiting the potential migratory signals induced by the disintegrin-like domain

Erratum

Erratum to: Involvement of DNMT 3B promotes epithelial-mesenchymal transition and gene expression profile of invasive head and neck squamous cell carcinomas cell lines

Study protocol

A phase Ia/Ib clinical trial of metronomic chemotherapy based on a mathematical model of oral vinorelbine in metastatic non-small cell lung cancer and malignant pleural mesothelioma: rationale and study protocol

Research article

Factors influencing diagnosis delay of advanced breast cancer in Moroccan women

Research article

Enhanced immunity in a mouse model of malignant glioma is mediated by a therapeutic ketogenic diet

Research article

After low and high dose-rate interstitial brachytherapy followed by IMRT radiotherapy for intermediate and high risk prostate cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits